Literature DB >> 15527089

Skull base surgery for benign skull base tumors.

Ketan R Bulsara1, Ossama Al-Mefty.   

Abstract

The use of skull base techniques in the treatment of benign skull base tumors has allowed access to areas of the brain once considered inaccessible. The most common benign skull base tumors encountered in neurosurgical practice are benign meningiomas, schwannomas, and glomus jugulare tumors. Gross total resection of these lesions gives patients the best possible chance of a cure. In this paper, we review the rationale for the use of skull base surgery techniques for benign skull base tumors.

Entities:  

Mesh:

Year:  2004        PMID: 15527089     DOI: 10.1023/b:neon.0000041881.59775.d5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  73 in total

1.  Jugular foramen: microscopic anatomic features and implications for neural preservation with reference to glomus tumors involving the temporal bone.

Authors:  C Sen; K Hague; R Kacchara; A Jenkins; S Das; P Catalano
Journal:  Neurosurgery       Date:  2001-04       Impact factor: 4.654

2.  Long-term follow-up of patients with meningiomas involving the cavernous sinus: recurrence, progression, and quality of life.

Authors:  O De Jesús; L N Sekhar; H K Parikh; D C Wright; D P Wagner
Journal:  Neurosurgery       Date:  1996-11       Impact factor: 4.654

3.  Basic surgical principles of neurotologic skull base surgery.

Authors:  C G Jackson
Journal:  Laryngoscope       Date:  1993-11       Impact factor: 3.325

4.  Incidence and clinical features of asymptomatic meningiomas.

Authors:  J Kuratsu; M Kochi; Y Ushio
Journal:  J Neurosurg       Date:  2000-05       Impact factor: 5.115

5.  Gamma knife radiosurgery in the management of cavernous sinus meningiomas.

Authors:  P H Roche; J Régis; H Dufour; H D Fournier; C Delsanti; W Pellet; F Grisoli; J C Peragut
Journal:  J Neurosurg       Date:  2000-12       Impact factor: 5.115

6.  Long-term results of treatment for glomus jugulare and glomus vagale tumors with radiotherapy.

Authors:  J M Cole; D Beiler
Journal:  Laryngoscope       Date:  1994-12       Impact factor: 3.325

7.  Comparison of conventional and skull base surgical approaches for the excision of trigeminal neurinomas.

Authors:  J M Taha; J M Tew; H R van Loveren; J T Keller; M el-Kalliny
Journal:  J Neurosurg       Date:  1995-05       Impact factor: 5.115

8.  Meningiomas of the space of the cavernous sinus.

Authors:  E Knosp; A Perneczky; W T Koos; G Fries; C Matula
Journal:  Neurosurgery       Date:  1996-03       Impact factor: 4.654

9.  Outcome of aggressive removal of cavernous sinus meningiomas.

Authors:  F DeMonte; H K Smith; O al-Mefty
Journal:  J Neurosurg       Date:  1994-08       Impact factor: 5.115

10.  Frontotemporal epidural approach to trigeminal neurinomas.

Authors:  V V Dolenc
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

View more
  4 in total

1.  Surgery for petroclival meningiomas: a comprehensive review of outcomes in the skull base surgery era.

Authors:  Michael L Diluna; Ketan R Bulsara
Journal:  Skull Base       Date:  2010-09

2.  5-Aminolevulinic acid-induced protoporphyrin IX fluorescence in meningioma: qualitative and quantitative measurements in vivo.

Authors:  Pablo A Valdes; Kimon Bekelis; Brent T Harris; Brian C Wilson; Frederic Leblond; Anthony Kim; Nathan E Simmons; Kadir Erkmen; Keith D Paulsen; David W Roberts
Journal:  Neurosurgery       Date:  2014-03       Impact factor: 4.654

3.  Quantitative and qualitative 5-aminolevulinic acid-induced protoporphyrin IX fluorescence in skull base meningiomas.

Authors:  Kimon Bekelis; Pablo A Valdés; Kadir Erkmen; Frederic Leblond; Anthony Kim; Brian C Wilson; Brent T Harris; Keith D Paulsen; David W Roberts
Journal:  Neurosurg Focus       Date:  2011-05       Impact factor: 4.047

Review 4.  Magnetic resonance-guided focused ultrasound: a new technology for clinical neurosciences.

Authors:  Ferenc A Jolesz; Nathan J McDannold
Journal:  Neurol Clin       Date:  2013-11-08       Impact factor: 3.806

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.